Press Releases

Date Title and Summary    
Toggle Summary Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress
ROCKVILLE, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it will present updated preliminary data from the Phase IIa study
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors
ROCKVILLE, Md., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced its founder, Chang Ahn, Ph.D., retired on August 31, 2017 from his
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
Patent Protection Extended until 2034
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
ROCKVILLE, Md., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has distributed to shareholders a mid-year update letter
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results
Presented Preliminary Clinical Data on RX-3117 in Bladder Cancer at the American Society of Clinical Oncologists (ASCO) Annual Meeting Strengthened Financial Position with a $10 million Registered Direct Offering ROCKVILLE, Md., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
Patent Protection for RX-3117 Extended until 2036
View HTML Print
Toggle Summary Rexahn Announces $10 Million Registered Direct Offering
ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 3.03 million shares of its common stock and warrants exercisable for up to approximately
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Metastatic Bladder Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments Stage 2 of the Study has Begun, Based on Positive Preliminary Efficacy Results from Stage 1
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
ROCKVILLE, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it will present preliminary data from the Phase IIa study of
View HTML Print
Toggle Summary Rexahn Effects 1-for-10 Reverse Stock Split
ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) ("Rexahn" or the "Company"), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that the Company's previously announced
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy